Yes this is a great deal, for something that the market held...

Yes this is a great deal, for something that the market held little value for (me too).

The same can be said for the SCLC phase 2. As the company said that would not pursue commercialisation. But if the update (due with 36 days) confirms cancer stem cell targeting, than we could have a huge jump in our valuation.

Other news expected is the quarterly, which shouldn't be too bad reading with $2.9m fonda income, over $2m R&D rebate and spp funds. Will we start to see costs coming down too (as the phase 3 trial numbers start to drop).

Then there is the next lot of fonda figures from Dr Reddys in about 25 days. hopefully profit margins are increasing as production savings kick in more.

And we know that hungry AstraZeneca have been casting an eye of acl. Any good HyACT data and they may get tempted!

Plenty to look forward too atm imho.